• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 1, 2019

View Archived Issues

Abpro inks $4B bispecifics development deal with China's NJCTTQ, aiming to progress pipeline

A new U.S.-China drug discovery deal focused on developing bispecific therapies for cancer could bring Woburn, Mass.-based Abpro Therapeutics Inc. as much $4 billion, including $60 million in near-term R&D funding from its Chinese partner, NJCTTQ, a subsidiary of Nanjing Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Outside of China and Thailand, Abpro will retain all commercial rights for any approved molecules, while NJCTTQ will retain rights in China. Read More

Novavax moving ahead despite miss in phase III RSV trial

Novavax Inc. execs tried to shift the focus to promising secondary and exploratory endpoint data showing efficacy of its Resvax respiratory syncytial virus (RSV) vaccine on the severe impacts of RSV infection, but Wall Street refused to be diverted Thursday, sending company shares (NASDAQ:NVAX) to a 52-week low on news of the primary endpoint miss in the phase III Prepare maternal immunization study. Read More

Horizon shine: New dawn for TED patients, phase III data opening door to BLA

The dataset that emerged from Dublin-based Horizon Pharma plc's phase III trial with teprotumumab for active thyroid eye disease (TED) is "not just OK – it's amazing," said Raymond Douglas, co-principal investigator in the phase II and phase III programs with the compound. Read More

FDA races full throttle ahead following historic shutdown

The five-week government shutdown that ended earlier this month was "the most difficult operational challenge we have faced in modern times," FDA Commissioner Scott Gottlieb told a House Appropriations subcommittee Wednesday. Read More

Sarepta inks deal with diagnostic firm Centogene to identify DMD patients in the MENA region

Centogene AG is teaming up with Sarepta Therapeutics Inc., of Cambridge, Mass., to identify patients with Duchenne muscular dystrophy (DMD) in the Middle East and North Africa region. As part of the collaboration, Rostock, Germany-based Centogene will perform complete molecular diagnostic testing, as well as provide diagnostic services to physicians treating patients exhibiting symptoms related to DMD. Read More

Indian biotech gearing up to use of data analytics, artificial intelligence

HYDERABAD, India – Indian pharma companies have started taking baby steps toward using data analytics and artificial intelligence in drug discovery and development, joining a global trend of pharma companies embracing digital and cloud technologies. But those efforts are still ad-hoc and experimental. Read More

Rani says robotic, auto-injection pill shows safety in first trial

Startup Rani Therapeutics LLC has gotten positive safety results in a first-in-human trial of its pill that's designed to enable painless injections of biologic drugs into the small intestine. Later this year, the San Jose, Calif.-based company plans to start a clinical trial with the robotic pill that includes a drug-filled resorbable needle – the initial safety test was without any drug. Read More

Other news to note

Gain Therapeutics SA, of Lugano, Switzerland, said it received funding support from The Michael J. Fox Foundation for Parkinson's Research and The Silverstein Foundation for Parkinson's with GBA to advance its noncompetitive molecular chaperones for Parkinson's disease. The grant support recognizes the company's therapeutic approach for Parkinson's with mutations in the glucocerebrosidase (GBA) gene. Read More

Regulatory front

The FDA warned Canarx Services Inc. this week that if it doesn't cease its business practice of supplying misbranded drugs to people in the U.S., it could face seizure or an injunction. Read More

Earnings

Pacira Pharmaceuticals Inc., of Parsippany, N.J., reported fourth-quarter GAAP net income of $8.3 million, or 20 cents per diluted share, and full-year 2018 GAAP net loss of $500,000, or 1 cent per basic and diluted share, on fourth-quarter Exparel (bupivacaine extended release) net sales of $94.4 million – a 20 percent increase over $78.7 million in the same period in 2017 – and full-year 2018 net sales of $331.1 million, a 17 percent increase over $282.9 million reported in 2017.  Read More

Financings

Kaleido Biosciences Inc., of Lexington, Mass., priced its IPO of 5 million shares at $15, $5 below the low end of its intended range, to raise $75 million. Kaleido granted underwriters a 30-day option to purchase up to 750,000 additional shares, potentially adding $11.25 million.  Read More

Clinical data for Feb. 28, 2019

Read More

Regulatory actions for Feb. 28, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe